Kangstem Biotech Co. Ltd - Asset Resilience Ratio

Latest as of March 2026: 42.31%

Kangstem Biotech Co. Ltd (217730) has an Asset Resilience Ratio of 42.31% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Kangstem Biotech Co. Ltd (217730) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩31.50 Billion

≈ $21.35 Million USD Cash + Short-term Investments

Total Assets

₩74.45 Billion

≈ $50.45 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Kangstem Biotech Co. Ltd's Asset Resilience Ratio has changed over time. See Kangstem Biotech Co. Ltd (217730) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Kangstem Biotech Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 217730 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩31.50 Billion	42.31%
Total Liquid Assets	₩31.50 Billion	42.31%

Asset Resilience Insights

Very High Liquidity: Kangstem Biotech Co. Ltd maintains exceptional liquid asset reserves at 42.31% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Kangstem Biotech Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Kangstem Biotech Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Kangstem Biotech Co. Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Kangstem Biotech Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	44.91%	₩36.60 Billion ≈ $24.80 Million	₩81.49 Billion ≈ $55.23 Million	+12.28pp
2024-12-31	32.63%	₩18.27 Billion ≈ $12.38 Million	₩55.99 Billion ≈ $37.94 Million	-13.35pp
2023-12-31	45.98%	₩37.36 Billion ≈ $25.32 Million	₩81.25 Billion ≈ $55.06 Million	+0.47pp
2022-12-31	45.51%	₩36.68 Billion ≈ $24.86 Million	₩80.59 Billion ≈ $54.62 Million	-9.33pp
2021-12-31	54.84%	₩56.57 Billion ≈ $38.34 Million	₩103.15 Billion ≈ $69.90 Million	+9.23pp
2020-12-31	45.61%	₩37.63 Billion ≈ $25.50 Million	₩82.51 Billion ≈ $55.91 Million	+32.88pp
2019-12-31	12.73%	₩14.47 Billion ≈ $9.81 Million	₩113.64 Billion ≈ $77.01 Million	-2.52pp
2018-12-31	15.25%	₩11.16 Billion ≈ $7.56 Million	₩73.19 Billion ≈ $49.60 Million	-8.51pp
2017-12-31	23.76%	₩10.91 Billion ≈ $7.39 Million	₩45.91 Billion ≈ $31.12 Million	-25.37pp
2016-12-31	49.13%	₩23.31 Billion ≈ $15.80 Million	₩47.44 Billion ≈ $32.15 Million	--

pp = percentage points

About Kangstem Biotech Co. Ltd

KQ:217730 Korea Biotechnology

Market Cap

$160.30 Million

₩236.55 Billion KRW

Market Cap Rank

#17487 Global

#720 in Korea

Share Price

₩2515.00

Change (1 day)

-6.85%

52-Week Range

₩1171.00 - ₩4615.00

All Time High

₩18836.30